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Abstract. A ‘paradoxical response’ to cancer treatment 
is a term used to describe the emergence of unexpected 
new lesions and the progression of existing lesions, despite 
appropriate and effective therapy. ‘Pseudo-progression’ is a 
phenomenon in which lymphocytes activated by an immune 
checkpoint inhibitor accumulate in a tumor and expand its 
shadow, mimicking enlargement of the primary lesion or 
development of a new metastatic lesion. Patients receiving 
cancer chemotherapy may respond differently to treatment, 
by exhibiting a response, deterioration, or the simultaneous 
occurrence of both. These variations may be attributed to the 
heterogeneity of the cancer. However, differences in the tempo-
rary response to epidermal growth factor receptor-tyrosine 
kinase inhibitor (EGFR-TKI) treatment are rarely observed. 
If such a phenomenon is observed, it should not affect the 
evaluation of the therapeutic effect or be considered as an 
indication for the discontinuation of treatment. We herein 
report a rare case of a transient increase in carcinomatous 
pleural fluid as a paradoxical response to osimertinib treat-
ment in a patient with T790M-mutated lung adenocarcinoma. 
The primary lesion and pulmonary metastases responded well 
to therapy. Although this paradoxical response is very rare, of 
non-malignant nature, and does not usually require treatment 
modification of, physicians must acknowledge that it is not a 
clinically discouraging characteristic when using EGFR-TKI 
to treat T790M-mutated lung adenocarcinoma.
Introduction
A ‘paradoxical response’ to cancer treatment is the emergence 
of unexpected new lesions and/or the progression of existing 
lesions, despite appropriate and effective therapy. This term 
is commonly used in association with anti-tuberculosis treat-
ment, where it describes a phenomenon observed in some 
patients with pulmonary and pleural tuberculosis, tuber-
culous lymphadenitis and intracranial tuberculoma (1-5). 
‘Pseudo-progression’ is another term used to describe a 
phenomenon in which lymphocytes activated by an immune 
checkpoint inhibitor accumulate in a tumor to expand its 
shadow, appearing as enlargement of the primary lesion 
or development of a new metastatic lesion. A proportion of 
patients treated with nivolumab exhibit pseudo-progression, in 
which transient disease progression is followed by a response 
to an immune checkpoint inhibitor (6-10). Cancer patients 
may respond differently to chemotherapy by exhibiting a 
response, deterioration, or occasionally simultaneous occur-
rence of both. These different responses may be attributed to 
the heterogeneity of the cancer. However, differences in the 
transient responses to epidermal growth factor receptor-tyro-
sine kinase inhibitor (EGFR-TKI) treatment are rare and, 
should such a phenomenon be observed, it should not affect 
the evaluation of the therapeutic effect or be considered as an 
indication for discontinuation of treatment. We herein describe 
a case with a transient increase in the amount of carcinoma-
tous pleural fluid as a paradoxical response to osimertinib 
therapy for T790M-mutated lung adenocarcinoma, despite the 
primary lesion and pulmonary metastases responding well to 
this treatment. The aim of the present study was to report this 
phenomenon in order to raise physicians’ awareness of this 
rare occurrence.
Case report
A 58-year-old male patient was referred to the Mito Medical 
Center in January 2014 after experiencing dyspnea on exer-
tion for 1 month. The patient had been diagnosed 27 months 
prior with adenocarcinoma in the upper lobe of the right lung. 
An EGFR exon 19 deletion was identified. Due to multiple 
metastases in both lungs, platinum-based chemotherapy and 
gefitinib therapy were administered. As third‑line therapy, 
the patient received nivolumab therapy, but 3 months after 
the initiation of nivolumab therapy, a follow-up chest 
computed tomography (CT) scan revealed regrowth of the 
primary pulmonary lesion in the left upper lobe and appear-
ance of miliary pulmonary metastases and bilateral pleural 
fluid (Fig. 1). The serum carcinoembryonic antigen (CEA) 
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level increased from 252.4 to 340.2 ng/ml in 1 month. 
Thoracentesis was performed to obtain cytological speci-
mens. Cytology of the pleural fluid revealed adenocarcinoma 
cells. A T790M mutation, together with a deletion within exon 
19 of the EGFR gene, were identified. Osimertinib (80 mg 
once daily) was therefore prescribed as fourth-line treatment 
for the adenocarcinoma. A chest CT scan 1 month after the 
initiation of osimertinib treatment revealed shrinkage of the 
primary lesion and disappearance of pulmonary metastases, 
but an increase in the amount of pleural fluid (Fig. 2). A chest 
CT scan 1 month later revealed a decrease in the amount of 
the pleural fluid and tumor shrinkage (Fig. 3). In addition, the 
serum CEA level had decreased to 20.2 ng/ml. The patient 
currently remains on osimertinib treatment, without major 
adverse events or disease recurrence (last follow-up visit, 
June 2017).
Figure 2. Chest computed tomography scan 1 month after the initiation of osimertinib treatment revealed shrinkage of the primary lesion and disappearance 
of pulmonary metastases, but an increase in the amount of pleural fluid was observed (arrows).
Figure 1. Chest computed tomography scan revealed regrowth of the primary lesion in the left upper lobe of the lung, with appearance of miliary pulmonary 
metastases and bilateral pleural fluid.
Figure 3. Chest computed tomography scan 1 month later showed decrease of the amount of pleural fluid and tumor shrinkage.
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Discussion
Pleural fluid is commonly found in a disseminated form in 
lung adenocarcinoma patients with carcinomatous pleuritis. 
However, to the best of our knowledge, an increase in the 
amount of pleural fluid as a transient paradoxical response 
to osimertinib therapy in a patient with EGFR-mutated lung 
cancer has never been reported to date. A paradoxical aggra-
vation response, which is a phenomenon that appears despite 
effective chemotherapy for tuberculosis, is generally considered 
immune-mediated (1-5). Active tuberculosis leads to an immu-
nosuppressed state via an altered cell-mediated response (1-5). 
When active tuberculosis is controlled by appropriate treat-
ment, enhanced focal immune responses (immunological 
rebound) mobilize lymphocytes and macrophages at the site 
of lesions (2).
In a proportion of patients treated with nivolumab, 
an IgG4 antibody that targets the programmed cell death 
protein-1 on the T-cell surface, there is pseudo-progression 
followed by transient progression and then a response (6-8). 
This immune-related tumor response may result in a 
temporary increase in tumor size, regression, or emergence 
of new lesions, followed by a response to subsequent treat-
ment (10). The response itself may take longer compared 
with that observed using conventional cytotoxic drugs (10). 
This pseudo‑progression may be attributed to the inflamma-
tion, edema and necrosis that are associated with immune 
cell infiltration of the tumor deposits (9). This immuno-
logical response is important for characterizing the effects 
of immune checkpoint inhibitors, and is not observed with 
conventional cytotoxic drugs or other targeted therapeu-
tics (8). The patient presented herein developed an increase in 
pleural fluid after 1 month of osimertinib therapy for recur-
rent T790M-mutated lung adenocarcinoma. The mechanism 
underlying this phenomenon has not been fully elucidated, 
but it may be hypothesized that rapid death of cancer cells 
following successful treatment of pulmonary and pleural 
lesions released factors that stimulated the production of 
pleural fluid. Another possibility is that increased pleural 
fluid is caused by an imbalance between production and 
drainage. It was unclear whether there was increased pleural 
fluid production, impaired drainage of pleural fluid, or both. 
There was no evidence to suggest pleurisy, other than carci-
nomatous pleuritis. The pleural fluid was exudative, but there 
were no findings consistent with infectious or tuberculous 
pleural fluid. It is paradoxical that there was a temporary 
increase in the pleural fluid containing T790M-positive 
cancer cells, despite the prompt response of the pulmonary 
metastatic lesions to treatment. Recognizing this clinically 
frustrating, but non-malignant paradoxical response, is 
meaningful for clinicians, although treatment modification is 
unnecessary. It is important that clinicians are aware of this 
rare event, whilst simultaneously considering other causes of 
an inadequate response to treatment, such as incorrect diag-
nosis, inappropriate drug regimen, drug resistance, atypical 
infectious disease, adverse effect to therapeutic drugs, or the 
deterioration of the disease. An accumulation of knowledge in 
this aspect of malignancy and cancer management will ensure 
continuing improvement in patient care. Informed consent to 
the publication of the case details and associated images was 
obtained from the patient.
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